Targeting SARS-CoV-2 and host cell receptor interactions

Page view(s)
285
Checked on Apr 16, 2024
Targeting SARS-CoV-2 and host cell receptor interactions
Title:
Targeting SARS-CoV-2 and host cell receptor interactions
Journal Title:
Antiviral Research
Publication Date:
26 December 2022
Citation:
Lim, S. P. (2023). Targeting SARS-CoV-2 and host cell receptor interactions. Antiviral Research, 210, 105514. https://doi.org/10.1016/j.antiviral.2022.105514
Abstract:
Despite the availability of vaccines and therapeutics, continual genetic alterations render the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) a persistent threat, particularly for the immunocompromised and elderly. Through interactions of its spike (S) protein with different receptors and coreceptors on host cell surfaces, the virus enters the cell either via fusion with the plasma membrane or through endocytosis. Angiotensin-converting enzyme 2 (ACE2) has been identified as a key receptor utilized by SARS-CoV-2 and related human coronaviruses to mediate cell entry in the lung airways. Auxiliary SARS-CoV-2 entry receptors such as ASGPR1, Kremen protein 1, integrins have also been reported. In this review, therapeutic approaches to block SARS-CoV-2 and host cell receptor interactions are discussed.
License type:
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Funding Info:
This research is supported by core funding from: Experimental Drug Development Centre
Grant Reference no. : NRF2021-IE-IECF-001
Description:
ISSN:
0166-3542
Files uploaded: